IP Litigation: Patent
We are fortunate to advise world-class, industry-leading companies, helping them tackle novel, complex issues and push the boundaries of technological progress. Our ability and confidence to go to trial is our core strength; our deep bench of experienced trial lawyers represents companies in their most significant matters, helping them protect their intellectual property and launch products. Our lawyers pair extensive experience in the courtroom and the boardroom with a thorough understanding of science and technology.
Paul, Weiss secured a major appellate victory on behalf of Vanda Pharmaceuticals Inc. before the U.S. Court of Appeals for the Federal Circuit.
Paul, Weiss won a significant victory for Genentech, Inc. in litigation brought by Baxalta Inc. concerning Genentech’s HEMLIBRA®, a potentially life-changing treatment for hemophilia A.
Litigation partner Jennifer Wu has been named a New York Law Journal Rising Star for 2018.
Paul, Weiss won a major patent victory for Japanese LED maker Nichia Corporation when the Patent Trial and Appeal Board dismissed petitions by U.S. television maker VIZIO seeking a review of the validity of four Nichia patents.
Steven Baughman has joined the firm as a partner in its litigation department, resident in Washington, D.C. Mr. Baughman's practice will focus on patent and trade secret disputes, as well as trademark, copyright and other complex commercial matters.
Law360 has honored firm chair Brad Karp, corporate partners Robert Schumer and Marco Masotti, and litigation partners Ted Wells and Catherine Nyarady with 2016 MVP Awards. Brad and Ted were selected as MVPs in the sports practice area, Bob won the distinction for M&A, Marco for asset management and Catherine for life sciences.
The Patent Trial and Appeal Board (PTAB) is an administrative trial forum established by Congress to provide a faster, more efficient alternative to district court litigation for patent validity challenges.
Paul, Weiss client Nichi-Iko Pharmaceutical Co., Ltd., the largest generic drug manufacturer in Japan by sales, announced that it has agreed to acquire Sagent Pharmaceuticals, Inc. in an all-cash tender offer followed by a second-step cash merger, for a total consideration of approximately $736 million.